Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed, Refractory Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT06325748
What this trial is testing

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Who this might be right for
AML/MDSCD33 Expressing Hematological MalignanciesFLT3 Expressing Hematological Malignancies
Senti Biosciences 21
Early research (Phase 1)Study completedNCT03269136
What this trial is testing

PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer 101
Testing effectiveness (Phase 2)Study completedNCT00530816
What this trial is testing

Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Amgen 164
Early research (Phase 1)UnknownNCT04677452
What this trial is testing

Dose Exploration Study OF JWCAR129, BCMA-Targeted CART for RRMM

Who this might be right for
Safety and Efficacy
The First Affiliated Hospital of Soochow University 24
Testing effectiveness (Phase 2)UnknownNCT03931421
What this trial is testing

B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma
First Affiliated Hospital of Zhejiang University 30
Large-scale testing (Phase 3)Active Not RecruitingNCT06868667
What this trial is testing

Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 24
Not applicableNot Yet RecruitingNCT07564128
What this trial is testing

Infection Surveillance of R/R Multiple Myeloma Patients Treated With Elranatamab as Clinical Practice in Italy

Who this might be right for
Multiple Mieloma
Gruppo Italiano Malattie EMatologiche dell'Adulto 50
Early research (Phase 1)Ended earlyNCT02099539
What this trial is testing

QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Altor BioScience 19
Not applicableEnded earlyNCT00290628
What this trial is testing

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Who this might be right for
Chronic Myeloproliferative DisordersDiamond-blackfan AnemiaFanconi Anemia+6 more
Masonic Cancer Center, University of Minnesota 43
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06333509
What this trial is testing

Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL

Who this might be right for
Multiple MyelomaPrimary Plasma Cell Leukemia
CARsgen Therapeutics Co., Ltd. 166
Large-scale testing (Phase 3)Looking for participantsNCT07579234
What this trial is testing

A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Shandong New Time Pharmaceutical Co., LTD 261
Early research (Phase 1)Active Not RecruitingNCT04613557
What this trial is testing

Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapse/Refractory Multiple Myeloma
Celyad Oncology SA 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT02773030
What this trial is testing

Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 466
Testing effectiveness (Phase 2)Looking for participantsNCT06356571
What this trial is testing

Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Plasma Cell Myeloma Refractory
Sanofi 64
Early research (Phase 1)Study completedNCT03828292
What this trial is testing

An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 15
Large-scale testing (Phase 3)Study completedNCT00719563
What this trial is testing

American Ginseng in Treating Patients With Fatigue Caused by Cancer

Who this might be right for
Chronic Myeloproliferative DisordersFatigueLeukemia+7 more
Alliance for Clinical Trials in Oncology 364
Early research (Phase 1)Ended earlyNCT02579824
What this trial is testing

Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Myeloma
M.D. Anderson Cancer Center 14
Early research (Phase 1)Study completedNCT00104923
What this trial is testing

Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+1 more
California Cancer Consortium 29
Testing effectiveness (Phase 2)Active Not RecruitingNCT04302324
What this trial is testing

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

Who this might be right for
Multiple MyelomaRefractory Multiple MyelomaRelapse Multiple Myeloma
Weill Medical College of Cornell University 11
Testing effectiveness (Phase 2)Study completedNCT00027560
What this trial is testing

Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+2 more
Memorial Sloan Kettering Cancer Center 51
Next Page